Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.61 USD

0.61
582,907

+0.04 (6.31%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.62 +0.01 (1.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioLineRx Ltd. [BLRX]

Reports for Purchase

Showing records 181 - 200 ( 202 total )

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 181

06/11/2013

Company Report

Pages: 9

Inks a Deal for BL-8030 in HCV

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 182

05/13/2013

Company Report

Pages: 9

1Q13 Highlights Movement Across the Portfolio

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 183

04/18/2013

Company Report

Pages: 10

IBD Program Shows Promise

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 184

03/22/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 185

03/22/2013

Company Report

Pages: 9

Serious Problems for BL-1020

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 186

12/05/2012

Daily Note

Pages: 13

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 187

12/05/2012

Company Report

Pages: 15

Analyst Day Points to a Promising 2013

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 188

11/20/2012

Daily Note

Pages: 12

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 189

11/20/2012

Company Report

Pages: 10

3Q Progress

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 190

10/17/2012

Company Report

Pages: 7

BL-8020 Progresses and Other Thoughts

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 191

10/10/2012

Daily Note

Pages: 11

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 192

10/09/2012

Company Report

Pages: 9

Additional Cognition Data for BL-1020

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 193

09/25/2012

Daily Note

Pages: 12

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 194

09/24/2012

Company Report

Pages: 14

Notice of Allowance to Help BL-1020

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 195

09/12/2012

Daily Note

Pages: 10

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 196

09/11/2012

Company Report

Pages: 9

Licenses An Oncologic and Decent Ciliac Disease Data

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 197

08/16/2012

Daily Note

Pages: 19

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 198

08/16/2012

Company Report

Pages: 19

2Q12 and Some Progress

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 50.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 199

07/12/2012

Daily Note

Pages: 8

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: BioLineRx Ltd.

Industry: Medical - Drugs

Record: 200

07/11/2012

Company Report

Pages: 15

Competition is Flagging in Schizophrenia for BL-1020

Provider: Roth Capital Partners, Inc.

Analyst: HAZLETT R

Price: 50.00

Research Provided by a Third Party